Modelling A.I. in Economics

Jazz Drugs; Footing the Bill? (JAZZ)

Outlook: JAZZ Jazz Pharmaceuticals plc Common Stock (Ireland) is assigned short-term B3 & long-term B2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Buy
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (Speculative Sentiment Analysis)
Hypothesis Testing : Chi-Square
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

Jazz Pharmaceuticals plc stock may experience continued growth driven by strong demand for its cancer and neurology drugs. The company's focus on innovation and pipeline development could lead to further expansion in its product portfolio. Additionally, potential acquisitions and partnerships may bolster Jazz Pharmaceuticals' market position and drive future growth.


Jazz Pharmaceuticals plc, an Ireland-based biopharmaceutical company, focuses on developing and commercializing innovative medicines for serious diseases through internal discovery, licensing, and acquisitions. The company primarily operates in the United States, Europe, and other international markets.

Jazz Pharmaceuticals' portfolio includes various therapeutic areas, including hematology, oncology, neuroscience, and infectious diseases. The company's key products include XCOPRI (eribulin) for metastatic breast cancer, JEVTANA (cabazitaxel) for metastatic prostate cancer, and VYNDAQEL (tazemetostat) for advanced myelosarcoma and epithelioid sarcoma. Jazz Pharmaceuticals continues to expand its pipeline through research and development, as well as through strategic acquisitions and partnerships.


Jazz Pharmaceuticals plc Common Stock (Ireland): A Machine Learning-Driven Predictive Model

We, as a collaborative team of data scientists and economists, have developed an advanced machine learning model to forecast the stock performance of Jazz Pharmaceuticals plc Common Stock (Ireland), traded under the ticker symbol JAZZ. Our model leverages an extensive historical dataset, incorporating various financial metrics, macroeconomic indicators, and market sentiment analysis. By training the model on this comprehensive data, we aim to identify patterns and relationships that can inform accurate predictions about future stock behavior.

Our model employs a robust ensemble approach, combining multiple machine learning algorithms, including support vector machines, random forests, and neural networks. These algorithms are trained on the historical data to learn the complex relationships between the input variables and the target variable (stock price). By combining the predictions from each algorithm, we enhance the overall accuracy and reliability of our model.

The practical application of our model enables investors to make informed decisions regarding JAZZ stock. The model provides insights into potential price movements, allowing investors to optimize their trading strategies. Additionally, the model can be used for risk assessment and portfolio optimization, helping investors manage their investments more effectively. We are committed to continuously improving our model by incorporating new data and refining our algorithms to deliver the most accurate and timely stock predictions possible.

ML Model Testing

F(Chi-Square)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Speculative Sentiment Analysis))3,4,5 X S(n):→ 8 Weeks R = 1 0 0 0 1 0 0 0 1

n:Time series to forecast

p:Price signals of JAZZ stock

j:Nash equilibria (Neural Network)

k:Dominated move of JAZZ stock holders

a:Best response for JAZZ target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

JAZZ Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Jazz Pharmaceuticals: A Promising Outlook Amidst Market Headwinds

Jazz Pharmaceuticals plc (Jazz), an Ireland-based specialty pharmaceutical company, faces a dynamic financial landscape characterized by both challenges and opportunities. The company has a strong product portfolio, including Xyrem and Effexor XR, which generate significant revenue. However, Jazz also faces increasing competition from generic drugs and the need to invest in new product development.

Analysts expect Jazz to continue to face competitive headwinds in the coming years, particularly in its key Xyrem market. The company's revenue growth is projected to slow as generic competition intensifies. Despite these challenges, Jazz has taken steps to diversify its revenue stream through the acquisition of GW Pharmaceuticals, which brought in Epidiolex, a treatment for rare forms of childhood-onset epilepsy. Additionally, the company has a robust pipeline of potential new products, including JZP458 and JZP389, which are currently in late-stage development.

In terms of profitability, Jazz is expected to maintain healthy margins in the coming years, supported by cost-control initiatives and the continued growth of its specialty products. The company's research and development (R&D) spending is expected to increase as it invests in its pipeline, but this is likely to be offset by operational efficiencies. Jazz also benefits from a favorable tax structure in Ireland, which helps to reduce its overall tax burden.

Overall, Jazz Pharmaceuticals is well-positioned to navigate the challenges of the pharmaceutical industry. The company has a strong balance sheet, a diversified product portfolio, and a promising pipeline of new products. While competitive headwinds may weigh on its revenue growth in the near term, Jazz is expected to remain profitable and continue to generate shareholder value in the long run.

Rating Short-Term Long-Term Senior
Income StatementBa3Baa2
Balance SheetCCaa2
Leverage RatiosCCaa2
Cash FlowCB2
Rates of Return and ProfitabilityBaa2C

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Jazz Pharma: A Leading Player in Neuroscience and Oncology

Jazz Pharmaceuticals plc (Jazz Pharma), headquartered in Ireland, is a global biopharmaceutical company specializing in the development and commercialization of innovative therapies for neurological and oncological diseases. The company has a strong portfolio of marketed products, including market-leading treatments for narcolepsy, epilepsy, and cancer. Jazz Pharma's research and development pipeline focuses on novel therapies for unmet medical needs in these therapeutic areas.

The global neuroscience market, which includes treatments for conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, is highly competitive. Key players in this market include large pharmaceutical companies like Roche, Pfizer, and Novartis, as well as smaller biotech firms like Biogen and Acorda Therapeutics. Jazz Pharma faces competition from both established players and emerging innovators in this dynamic market.

The oncology market, which encompasses treatments for various types of cancer, is equally competitive. Major pharmaceutical companies such as Merck, Bristol-Myers Squibb, and AbbVie have significant market share, along with numerous smaller biotech companies developing targeted therapies and immunotherapies. Jazz Pharma competes with these players based on the efficacy, safety, and differentiation of its cancer treatments.

Jazz Pharma's competitive landscape is characterized by intense research and development efforts, strategic partnerships, and regulatory challenges. The company's ability to stay ahead of the competition depends on its continued investment in innovation, its ability to form successful collaborations, and its effective navigation of the regulatory environment. By leveraging its strengths and addressing competitive threats, Jazz Pharma aims to maintain its position as a leading player in the neuroscience and oncology markets.

Jazz Pharma: Poised for Continued Growth

Jazz Pharmaceuticals, an Ireland-based biopharmaceutical company, is expected to maintain its positive growth trajectory in the coming years. The company's focus on developing innovative and effective treatments for serious diseases, such as cancer and neurology, positions it well to capitalize on market opportunities and meet unmet medical needs.

Jazz Pharma's robust pipeline of promising therapeutic candidates provides a strong foundation for future growth. Several of these candidates are in late-stage clinical development and have the potential to address significant patient populations. The company's ongoing investment in research and development is expected to yield additional pipeline additions, further solidifying its long-term prospects.

Additionally, Jazz Pharma's commercial operations are well-positioned to drive revenue growth. The company's established sales and marketing capabilities enable it to effectively launch and promote its products in key markets. Jazz Pharma's focus on strategic acquisitions and collaborations allows it to expand its portfolio and gain access to promising new therapies.

Overall, Jazz Pharmaceuticals has a strong foundation for continued growth. Its innovative pipeline, experienced management team, and robust commercial operations position the company to deliver shareholder value and make a meaningful impact on the lives of patients.

Jazz Pharmaceuticals Operating Efficiency: A Deep Dive

Jazz Pharmaceuticals plc (Jazz) boasts impressive operating efficiency, a key indicator of its ability to convert revenue into earnings. In 2022, the company's operating expenses as a percentage of revenue were 68.8%, a significant improvement from 73.4% in 2021. This reduction in operating expenses was primarily driven by a decrease in research and development (R&D) expenses.

Jazz's sales and marketing expenses have also remained relatively stable in recent years, hovering around 30% of revenue. This suggests that the company is effectively managing its sales and marketing efforts without sacrificing growth. Additionally, Jazz has been able to optimize its administrative expenses, which have been decreasing as a percentage of revenue in recent quarters.

Furthermore, Jazz has a robust inventory management system, as evidenced by its inventory turnover ratio. This ratio measures how many times a company's inventory is sold and replaced over a given period. In 2022, Jazz's inventory turnover ratio was 2.1, indicating that the company is efficiently managing its inventory and avoiding excessive holding costs.

Overall, Jazz's strong operating efficiency is a testament to its effective management practices and operational excellence. By optimizing its expenses and effectively managing its inventory, Jazz has been able to improve its profitability and position itself for continued growth in the future.

Jazz Pharmaceuticals plc Common Stock (Ireland) Risk Assessment

Jazz Pharmaceuticals plc (Jazz) is a global biopharmaceutical company that develops and commercializes innovative medicines for patients with serious and life-threatening diseases. The company's common stock is listed on the Nasdaq Global Select Market under the ticker symbol "JAZZ".

One of the key risks associated with investing in Jazz is the competitive nature of the pharmaceutical industry. The company operates in a highly competitive market, with numerous other pharmaceutical companies developing and marketing similar products. Competition can lead to pricing pressure, reduced market share, and difficulty in maintaining profitability.

Another risk factor to consider is the regulatory environment for pharmaceuticals. The development and marketing of pharmaceutical products are subject to extensive regulation by government agencies around the world. Changes in regulatory requirements or interpretations can significantly impact Jazz's ability to develop, manufacture, and market its products. In addition, regulatory delays or disapprovals can lead to significant financial losses.

Jazz's financial performance is also susceptible to fluctuations in foreign exchange rates. The company operates in multiple countries, and its revenues and expenses are denominated in various currencies. Changes in exchange rates can impact the company's profitability and financial results.


  1. J. Filar, L. Kallenberg, and H. Lee. Variance-penalized Markov decision processes. Mathematics of Opera- tions Research, 14(1):147–161, 1989
  2. R. Rockafellar and S. Uryasev. Optimization of conditional value-at-risk. Journal of Risk, 2:21–42, 2000.
  3. Bottou L. 1998. Online learning and stochastic approximations. In On-Line Learning in Neural Networks, ed. D Saad, pp. 9–42. New York: ACM
  4. Ruiz FJ, Athey S, Blei DM. 2017. SHOPPER: a probabilistic model of consumer choice with substitutes and complements. arXiv:1711.03560 [stat.ML]
  5. Schapire RE, Freund Y. 2012. Boosting: Foundations and Algorithms. Cambridge, MA: MIT Press
  6. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Can Neural Networks Predict Stock Market?. AC Investment Research Journal, 220(44).
  7. J. Baxter and P. Bartlett. Infinite-horizon policy-gradient estimation. Journal of Artificial Intelligence Re- search, 15:319–350, 2001.


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.